WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the ...

LONDON, UK I October 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials ANCHOR-1 and ANCHOR-2, ...

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

GSK plc has announced positive results from its Phase III ANCHOR trials for depemokimab, a biologic treatment for chronic ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the ...

GSK said that both the Anchor-1 and Anchor-2 trials met their co-primary endpoints of a change from baseline in total endoscopic nasal polyp score after 52 weeks, as well as a change in mean nasal ...

YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the ...

He had developed meningitis and pus on his brain as a result of the sinus infection sinusitis ... and Mr Darcheville was ...

Chitogel Limited manufactures a natural ingredient based, post-operative, biodegradable hydrogel nasal dressing that is applied to the sinuses after endoscopic sinus surgery. It improves wound healing ...

According to dual board-certified otolaryngologist at ENT and Allergy Associates Dr. Ofer Jacobowitz, snoring — an event that ...

Dad-of-two Reece Darcheville died in 2017 after medics failed to recognise the seriousness of his condition and sent him home ...

Dad-of-two Reece Darcheville died in 2017 after medics failed to recognise the seriousness of his condition and sent him home ...